Description

Overview

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone. It was developed to investigate whether some metabolic effects associated with growth hormone could be separated from its growth-promoting activity. Research has focused primarily on lipid metabolism, body-composition endpoints, and more recently cartilage and musculoskeletal models. Human obesity studies did not establish AOD-9604 as an approved weight-management drug, so it is best understood as an investigational research compound rather than a proven therapeutic.

How It Works

Metabolic signaling: Experimental work has examined effects on lipolysis and lipogenesis without reproducing the full growth-promoting profile of intact growth hormone.
Growth-hormone-fragment biology: The molecule is used to study biological activity associated with a defined region of the growth-hormone sequence.
Cartilage research: Laboratory and translational studies have also explored cartilage and connective-tissue endpoints.

Research Areas

Lipid metabolism
Body-composition research
Cartilage biology
Growth-hormone-fragment signaling

Research / Study Context

Human metabolic studies: Dose-ranging and obesity studies evaluated body-weight and metabolic endpoints; results were not sufficient for drug approval.
Preclinical cartilage studies: Experimental models have evaluated chondrocyte, cartilage, and tissue-repair endpoints.

Key Research Findings

AOD-9604 remains investigational.
Human evidence for clinically meaningful weight reduction is limited.
Research interest extends beyond metabolism into cartilage and musculoskeletal biology.